| scholarly article | Q13442814 |
| P50 | author | Andrzej Myc | Q30902458 |
| P2093 | author name string | James R Baker | |
| Tarek Hamouda | |||
| Crystal Passmore | |||
| Jessica J O'Konek | |||
| Paul E Makidon | |||
| Ali Fattom | |||
| Vira Bitko | |||
| Jessie Pannu | |||
| Joseph A Zahn | |||
| Nicolas W Lukacs | |||
| P2860 | cites work | A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease | Q21560951 |
| Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis | Q24203706 | ||
| Evidence of a causal role of winter virus infection during infancy in early childhood asthma | Q24653420 | ||
| Mortality associated with influenza and respiratory syncytial virus in the United States | Q29615578 | ||
| Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis | Q29619821 | ||
| Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine | Q30421413 | ||
| Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine | Q33359620 | ||
| Risk of primary infection and reinfection with respiratory syncytial virus | Q34188122 | ||
| A novel subset of CD4+ TH2 memory/effector cells that produce inflammatory IL-17 cytokine and promote the exacerbation of chronic allergic asthma | Q34243351 | ||
| Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease | Q34330690 | ||
| The burden of respiratory syncytial virus infection in young children | Q34938343 | ||
| IL-17-induced pulmonary pathogenesis during respiratory viral infection and exacerbation of allergic disease. | Q35069985 | ||
| Advances in respiratory syncytial virus vaccine development. | Q35713904 | ||
| Role of interleukin-12 and stat-4 in the regulation of airway inflammation and hyperreactivity in respiratory syncytial virus infection | Q35746966 | ||
| A role for immune complexes in enhanced respiratory syncytial virus disease | Q36371267 | ||
| An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice | Q36500189 | ||
| T(H)-17 cells in the circle of immunity and autoimmunity | Q36765453 | ||
| Respiratory syncytial virus persistence in chronic obstructive pulmonary disease. | Q37280561 | ||
| Challenges in developing a pediatric RSV vaccine | Q37531753 | ||
| Nanoemulsion mucosal adjuvant uniquely activates cytokine production by nasal ciliated epithelium and induces dendritic cell trafficking. | Q37594498 | ||
| Induction of Th17 cellular immunity with a novel nanoemulsion adjuvant. | Q37724921 | ||
| Respiratory syncytial virus recombinant F protein (residues 255-278) induces a helper T cell type 1 immune response in mice | Q40113065 | ||
| Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy | Q40614352 | ||
| Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children | Q41077230 | ||
| Intranasal immunization of ferrets with commercial trivalent influenza vaccines formulated in a nanoemulsion-based adjuvant | Q42128915 | ||
| Importance of viral and bacterial infections in chronic obstructive pulmonary disease exacerbations | Q43543756 | ||
| Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine | Q43625547 | ||
| Induction of immune response to the 17 kDa OMPA Burkholderia cenocepacia polypeptide and protection against pulmonary infection in mice after nasal vaccination with an OMP nanoemulsion-based vaccine. | Q44335525 | ||
| Efficacy, immunogenicity and stability of a novel intranasal nanoemulsion-adjuvanted influenza vaccine in a murine model | Q45060401 | ||
| Role of neutralizing antibodies in adults with community-acquired pneumonia by respiratory syncytial virus | Q45360497 | ||
| A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease | Q45367066 | ||
| A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age. | Q45382330 | ||
| Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion. | Q45722189 | ||
| Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine | Q45762897 | ||
| Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit | Q45780126 | ||
| Respiratory syncytial virus-specific cell-mediated immune responses after vaccination with a purified fusion protein subunit vaccine | Q45781115 | ||
| Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine | Q45823297 | ||
| Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract | Q47953307 | ||
| Respiratory syncytial virus vaccine development | Q56893551 | ||
| IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge | Q58518610 | ||
| ACUTE RESPIRATORY DISEASE IN INFANCY AND CHILDHOOD: PRESENT UNDERSTANDING AND PROSPECTS FOR PREVENTION | Q78437662 | ||
| Respiratory syncytial virus infection in adults | Q80216008 | ||
| Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigens | Q82481907 | ||
| Immunology. An innate role for IL-17 | Q83759174 | ||
| P433 | issue | 3 | |
| P921 | main subject | immunization | Q1415366 |
| P304 | page(s) | 615-622 | |
| P577 | publication date | 2013-12-10 | |
| P1433 | published in | Human Vaccines & Immunotherapeutics | Q21072749 |
| P1476 | title | Intranasal immunization with W 80 5EC adjuvanted recombinant RSV rF-ptn enhances clearance of respiratory syncytial virus in a mouse model | |
| P478 | volume | 10 |
| Q35593603 | Formulation, high throughput in vitro screening and in vivo functional characterization of nanoemulsion-based intranasal vaccine adjuvants |
| Q90082678 | Intranasal nanoemulsion-adjuvanted HSV-2 subunit vaccine is effective as a prophylactic and therapeutic vaccine using the guinea pig model of genital herpes |
| Q37320191 | Intranasal nanoemulsion-based inactivated respiratory syncytial virus vaccines protect against viral challenge in cotton rats |
| Q55447639 | The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics. |
| Q64121043 | Topological Aspects of the Design of Nanocarriers for Therapeutic Peptides and Proteins |
Search more.